Swedish-based CDMO Recipharm announced at CPHI that it is “expanding its pharmaceutical development capabilities through targeted investments and the integration of cutting-edge technologies”. This, it said, will bolster services at both early- and late- stage development, giving it fully integrated services that cover the whole life cycle of a molecule. These additions comprise: